Genotyping Market Size, Trends, Share, Growth, Report 2023-2032
The global genotyping market was surpassed at USD 15.11 billion in 2022 and is expected to hit around USD 59.04 billion by 2032, growing at a CAGR of 14.60% from 2023 to 2032. The genotyping market in the United States was accounted for USD 644.5 million in 2022.
Key Pointers
Report Scope of the Genotyping Market
| Report Coverage | Details |
| Revenue Share of North America in 2022 | 39.55% |
| CAGR of Asia Pacific from 2023 to 2032 | 15.99% |
| Revenue Forecast by 2032 | USD 59.04 billion |
| Growth Rate from 2023 to 2032 | CAGR of 14.60% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Companies Covered | Illumina Inc.; Thermo Fisher Scientific Inc.; QIAGEN; F. Hoffmann-La Roche Ltd.; Fluidigm Corporation; Danaher Corporation; Agilent Technologies; Eurofins Scientific Inc.; GE Healthcare Inc.; Bio-Rad Laboratories Inc. |
The growth can be attributed to technological advancements, rising prevalence of cancer & genetic disorders, and increasing R&D funding for precision medicine research. COVID-19 has had a positive impact on the genotyping market, as the pandemic led to an increased demand for COVID-19 genotyping kits. SNP genotyping has been used for the detection of genetic variants of COVID-19.
Increase in government funding, especially for genomic research, by government bodies, and pharma & biotechnology companies to accelerate research is expected to drive the genotyping market. For instance, in September 2018, NIH granted USD 28.6 million to the “All of Us Research Program” for establishing three genome centers around the U.S. dedicated to precision medicine research.
The prevalence of chronic diseases such as cancer and genetic disease is increasing worldwide and is expected to drive demand for genotypic-based diagnostic testing. For instance, according to WHO, 19.1 million new cancer cases were diagnosed globally in 2020. Cancer-causing viruses such as Human Papilloma Virus (HPV) and Hepatitis B Virus (HBV)/Hepatitis C Virus (HCV) are also responsible for about 20% of cancer deaths worldwide. The number of cancer cases is expected to increase by around 70% over the next two decades, estimated based on population growth and aging. Therefore, the rising prevalence of cancer is expected to be a high-impact rendering driver of this market.
However, factors such as lack of skilled technicians, especially in developing countries, could hamper market growth, genotyping data analysis and management requires high technical knowhow. Currently, there is a relatively low number of professionals and experts working in this field in developing nations.
Strategic initiatives undertaken by local players are anticipated to contribute to market growth. For instance, in February 2021, VG Acquisition Corp. merged with 23andMe, a U.S.-based genetics and research company actively working with direct-to-consumer genotyping solutions. This merger would provide capital funds for their genetic consumer health business.
Product Insights
The reagents & kits segment held the largest share of 61.79% in 2022. It is expected to grow at a rapid CAGR during the forecast years due to increasing demand for genetic testing, rising investments in R&D, and increasing genotyping testing volumes.
Software & services segment is also anticipated to grow at a significant CAGR of 14.39% from 2023 to 2032 due to rise in the adoption of software-based services by research laboratories and academic institutions. Bioinformatics solutions improve the efficacy of sequencing methods and help avoid errors that occur in traditional sequencing methods. These services find application in agrigenomics, human diseases, animal livestock, and microbes. All the aforementioned factors are anticipated to propel market growth over the forecast period.
Technology Insights
The sequencing segment dominated the market in 2022 with a share of 21.08%. It is expected to grow at a lucrative rate during the forecast period due to improved specificity and better ability to detect low expression & differentially expressed genes than other techniques. Genotyping by sequencing also helps perform comparative analysis across samples without the need for a reference genome.
PCR segment is projected to grow at a CAGR of 11.66% from 2023 to 2032 due to the increasing demand for advanced diagnostic techniques, rising number of CROs, forensic & research laboratories and growing prevalence of diseases such as chronic diseases & genetic disorders are major factors expected to drive market growth.
Application Insights
Diagnostics and personalized medicine segment accounted for the highest share of 33.75% in 2022 owing to the rising adoption of genotyping products for research and the increasing need for the diagnosis of genetic diseases. In addition, strategic collaborations among players are expected to boost market growth. For instance, in February 2019, Centogene entered into a strategic partnership with Sarepta Therapeutics, Inc. to diagnose Duchenne muscular dystrophy patients in the MENA region.
Pharmacogenomics is expected to witness the fastest CAGR of 15.38% from 2023 to 2032. Genotyping helps identify patients suitable for a particular drug based on the patients’ genetic make-up. Identifying population subsets that are responsive or non-responsive help deliver tailor-made treatment to these individuals with different genetic makeup and helps reduce clinical trial attrition. Moreover, key players play an active role by providing solutions for pharmacogenomics studies. For instance, RT PCR solution by Thermo Fisher Scientific for pharmacogenomic testing includes TaqMan assays and QuantStudio instruments. It also provides a PharmacoScan solution with a PharmacoScan Assay Kit.
End-use Insights
Diagnostics and research laboratories segment held the largest share of 36.27% in 2022 owing to the rising adoption of genotyping products for research and the increasing need for diagnosis of genetic diseases & cancer. In addition, the growing prevalence of cancer also increases the demand for diagnostic tests, such as cancer genotyping assays, which is expected to drive the market.
The pharmaceutical and biopharmaceutical companies segment is expected to grow at a significant CAGR of 14.89% during the forecast period. Growing need for pharmacogenomics in the drug development process and FDA recommendations to include pharmacogenomics studies & genotyping in the drug discovery process are factors expected to drive market growth. Companies actively use pharmacogenomics to develop novel drugs. For instance, Pfizer is conducting a genotyping-based clinical trial to study the efficacy of Talazoparib in patients with somatic BRCA mutant resistant metastatic breast cancer. Thus, the rising number of clinical trials based on pharmacogenomics is likely to drive segment growth.
Regional Insights
North America accounted for the largest market share of 39.55% in 2022 due to the increasing adoption of technologically advanced products, the presence of major pharmaceutical & biopharmaceutical companies, proactive government measures, and advances in healthcare infrastructure. The presence of major players in this region is another key factor responsible for high market share.
Asia Pacific is anticipated to exhibit the fastest CAGR of 15.99% during the forecast period due to the presence of enormous untapped opportunities and increasing number of clinical trials being conducted in this region. This growth can also be attributed to other factors, such as technological advancements and the growing pharma and biopharma sector in the region.
Genotyping Market Segmentations:
By Product
By Technology
By Application
By End-use
By Regional
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Genotyping Market
5.1. COVID-19 Landscape: Genotyping Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Genotyping Market, By Product
8.1. Genotyping Market, by Product, 2023-2032
8.1.1. Instruments
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Reagents & Kits
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Software and Services
8.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Genotyping Market, By Technology
9.1. Genotyping Market, by Technology, 2023-2032
9.1.1. PCR
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Capillary Electrophoresis
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Microarrays
9.1.3.1. Market Revenue and Forecast (2020-2032)
9.1.4. Sequencing
9.1.4.1. Market Revenue and Forecast (2020-2032)
9.1.5. Mass Spectrometry
9.1.5.1. Market Revenue and Forecast (2020-2032)
9.1.6. Others
9.1.6.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Genotyping Market, By Application
10.1. Genotyping Market, by Application, 2023-2032
10.1.1. Pharmacogenomics
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Diagnostics and Personalized Medicine
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Agricultural Biotechnology
10.1.3.1. Market Revenue and Forecast (2020-2032)
10.1.4. Animal Genetics
10.1.4.1. Market Revenue and Forecast (2020-2032)
10.1.5. Others
10.1.5.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Genotyping Market, By End-use
11.1. Genotyping Market, by End-use, 2023-2032
11.1.1. Pharmaceutical and Biopharmaceutical Companies
11.1.1.1. Market Revenue and Forecast (2020-2032)
11.1.2. Diagnostics and Research Laboratories
11.1.2.1. Market Revenue and Forecast (2020-2032)
11.1.3. Academic Institutes
11.1.3.1. Market Revenue and Forecast (2020-2032)
11.1.4. Others
11.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 12. Global Genotyping Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Product (2020-2032)
12.1.2. Market Revenue and Forecast, by Technology (2020-2032)
12.1.3. Market Revenue and Forecast, by Application (2020-2032)
12.1.4. Market Revenue and Forecast, by End-use (2020-2032)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Product (2020-2032)
12.1.5.2. Market Revenue and Forecast, by Technology (2020-2032)
12.1.5.3. Market Revenue and Forecast, by Application (2020-2032)
12.1.5.4. Market Revenue and Forecast, by End-use (2020-2032)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Product (2020-2032)
12.1.6.2. Market Revenue and Forecast, by Technology (2020-2032)
12.1.6.3. Market Revenue and Forecast, by Application (2020-2032)
12.1.6.4. Market Revenue and Forecast, by End-use (2020-2032)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Product (2020-2032)
12.2.2. Market Revenue and Forecast, by Technology (2020-2032)
12.2.3. Market Revenue and Forecast, by Application (2020-2032)
12.2.4. Market Revenue and Forecast, by End-use (2020-2032)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Product (2020-2032)
12.2.5.2. Market Revenue and Forecast, by Technology (2020-2032)
12.2.5.3. Market Revenue and Forecast, by Application (2020-2032)
12.2.5.4. Market Revenue and Forecast, by End-use (2020-2032)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Product (2020-2032)
12.2.6.2. Market Revenue and Forecast, by Technology (2020-2032)
12.2.6.3. Market Revenue and Forecast, by Application (2020-2032)
12.2.6.4. Market Revenue and Forecast, by End-use (2020-2032)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Product (2020-2032)
12.2.7.2. Market Revenue and Forecast, by Technology (2020-2032)
12.2.7.3. Market Revenue and Forecast, by Application (2020-2032)
12.2.7.4. Market Revenue and Forecast, by End-use (2020-2032)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Product (2020-2032)
12.2.8.2. Market Revenue and Forecast, by Technology (2020-2032)
12.2.8.3. Market Revenue and Forecast, by Application (2020-2032)
12.2.8.4. Market Revenue and Forecast, by End-use (2020-2032)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Product (2020-2032)
12.3.2. Market Revenue and Forecast, by Technology (2020-2032)
12.3.3. Market Revenue and Forecast, by Application (2020-2032)
12.3.4. Market Revenue and Forecast, by End-use (2020-2032)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Product (2020-2032)
12.3.5.2. Market Revenue and Forecast, by Technology (2020-2032)
12.3.5.3. Market Revenue and Forecast, by Application (2020-2032)
12.3.5.4. Market Revenue and Forecast, by End-use (2020-2032)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Product (2020-2032)
12.3.6.2. Market Revenue and Forecast, by Technology (2020-2032)
12.3.6.3. Market Revenue and Forecast, by Application (2020-2032)
12.3.6.4. Market Revenue and Forecast, by End-use (2020-2032)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Product (2020-2032)
12.3.7.2. Market Revenue and Forecast, by Technology (2020-2032)
12.3.7.3. Market Revenue and Forecast, by Application (2020-2032)
12.3.7.4. Market Revenue and Forecast, by End-use (2020-2032)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Product (2020-2032)
12.3.8.2. Market Revenue and Forecast, by Technology (2020-2032)
12.3.8.3. Market Revenue and Forecast, by Application (2020-2032)
12.3.8.4. Market Revenue and Forecast, by End-use (2020-2032)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Product (2020-2032)
12.4.2. Market Revenue and Forecast, by Technology (2020-2032)
12.4.3. Market Revenue and Forecast, by Application (2020-2032)
12.4.4. Market Revenue and Forecast, by End-use (2020-2032)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Product (2020-2032)
12.4.5.2. Market Revenue and Forecast, by Technology (2020-2032)
12.4.5.3. Market Revenue and Forecast, by Application (2020-2032)
12.4.5.4. Market Revenue and Forecast, by End-use (2020-2032)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Product (2020-2032)
12.4.6.2. Market Revenue and Forecast, by Technology (2020-2032)
12.4.6.3. Market Revenue and Forecast, by Application (2020-2032)
12.4.6.4. Market Revenue and Forecast, by End-use (2020-2032)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Product (2020-2032)
12.4.7.2. Market Revenue and Forecast, by Technology (2020-2032)
12.4.7.3. Market Revenue and Forecast, by Application (2020-2032)
12.4.7.4. Market Revenue and Forecast, by End-use (2020-2032)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Product (2020-2032)
12.4.8.2. Market Revenue and Forecast, by Technology (2020-2032)
12.4.8.3. Market Revenue and Forecast, by Application (2020-2032)
12.4.8.4. Market Revenue and Forecast, by End-use (2020-2032)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Product (2020-2032)
12.5.2. Market Revenue and Forecast, by Technology (2020-2032)
12.5.3. Market Revenue and Forecast, by Application (2020-2032)
12.5.4. Market Revenue and Forecast, by End-use (2020-2032)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Product (2020-2032)
12.5.5.2. Market Revenue and Forecast, by Technology (2020-2032)
12.5.5.3. Market Revenue and Forecast, by Application (2020-2032)
12.5.5.4. Market Revenue and Forecast, by End-use (2020-2032)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Product (2020-2032)
12.5.6.2. Market Revenue and Forecast, by Technology (2020-2032)
12.5.6.3. Market Revenue and Forecast, by Application (2020-2032)
12.5.6.4. Market Revenue and Forecast, by End-use (2020-2032)
Chapter 13. Company Profiles
13.1. Illumina Inc.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Thermo Fisher Scientific Inc.
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. QIAGEN
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. F. Hoffmann-La Roche Ltd.
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Fluidigm Corporation
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Danaher Corporation
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Agilent Technologies
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Eurofins Scientific Inc.
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. GE Healthcare Inc.
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Bio-Rad Laboratories Inc.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers